期刊
INFLAMMATORY BOWEL DISEASES
卷 11, 期 11, 页码 986-991出版社
OXFORD UNIV PRESS INC
DOI: 10.1097/01.MIB.0000186408.07769.78
关键词
autoantibodies; Crohn's disease; infliximab
Background: Treatment of Crohn's disease (CD) by infliximab has been associated with the induction of antinuclear (ANA) and antidouble stranded DNA (dsDNA) autoantibodies. As yet, little is known about the effect of the humoral response induced by infliximab oil the production of other organ-specific or nonorgan-specific autoantibodies. Methods: Thirty-five patients with CD treated with repeated infusions of infliximab were prospectively studied. Thirty-two patients with CD who had never received infliximab served as controls. A large panel of autoantibodies directed against phospholipid, beta 2-glycoprotein 1, mitochondria, smooth muscle, liver-kidney microsomes, filaggrin, thyroid, adrenals, and rheumatoid factor was tested along with ANA and anti-dsDNA autoantibodies during 1 year of intermittent treatment with infliximab. Autoantibodies were detected using the appropriate methods (i.e., indirect immunofluorescence, a radioimmunological technique, and ELISA assays). Results: Induction of ANA and anti-dsDNA autoantibodies was observed in 53% and 35% of infliximab-treated patients with CD, respectively. Overall, no other organ-specific or nonorgan-specific autoantibodies were detected during follow-up. A single patient who developed ANA and anti-dsDNA autoantibodies showed clinical features consistent with drug-induced lupus, which quickly resolved after discontinuation of infliximab. The other patients with CD receiving infliximab did not develop any clinical symptoms of autoimmunity. Conclusions: The humoral response induced by infliximab was restricted to ANA and anti-dsDNA autoantibodies, which persist for up to 1 year of follow-up. We confirmed the significant prevalence of such autoantibodies induced by infliximab in CD, but they are not generally associated with clinical signs of autoimmunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据